Type:

Other

Description:

Access to the article is free, however registration and sign-in are required. Tuberculosis (TB) kills 2 million people annually worldwide and imposes huge costs on communities, particularly those in developing countries. Yet no new drugs for TB have been discovered in the past 40 years. This is set to change, as Cole and Alzari report in their Perspective, with the discovery of a diarylquinoline compound that is highly active against a broad range of mycobacterial species including both the drug-sensitive and drug-resistant forms of M. tuberculosis, the bacterium that causes TB (Andries et al.).

Subjects:

    Education Levels:

      Keywords:

      oai:nsdl.org:2200/20110722030236292T,Mycobacterium tuberculosis,NSDL,NSDL_SetSpec_BEN,combination therapy,inhiibitors of ATP synthase,multidrug-resistant tuberculosis (MDR-TB),R207910,bactericidal agents,directly observed therapy short-course (DOTS)

      Language:

      English

      Access Privileges:

      Public - Available to anyone

      License Deed:

      Creative Commons Attribution Non-Commercial Share Alike

      Collections:

      None
      This resource has not yet been aligned.
      Curriki Rating
      'NR' - This resource has not been rated
      NR
      'NR' - This resource has not been rated

      This resource has not yet been reviewed.

      Not Rated Yet.

      Non-profit Tax ID # 203478467